A novel JAK/ROCK inhibitor, CPL409116, demonstrates potent efficacy in the mouse model of systemic lupus erythematosus
Systemic lupus erythematosus is a chronic inflammatory disease, in which treatment is still limited due to suboptimal efficacy and toxicities associated with the available therapies. JAK kinases are well known to play an important role in systemic lupus erythematous. There is growing evidence that R...
Saved in:
Main Authors: | Maria Dulak-Lis (Author), Anna Bujak (Author), Kamila Gala (Author), Martyna Banach (Author), Urszula Kędzierska (Author), Joanna Miszkiel (Author), Joanna Hucz-Kalitowska (Author), Michał Mroczkiewicz (Author), Bartosz Stypik (Author), Krzysztof Szymczak (Author), Paweł Gunerka (Author), Krzysztof Dubiel (Author), Beata M. Zygmunt (Author), Maciej Wieczorek (Author), Jerzy S. Pieczykolan (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2021-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Development of a Formulation and In Vitro Evaluation of a Pulmonary Drug Delivery System for a Novel Janus Kinase (JAK) Inhibitor, CPL409116
by: Aleksandra Rzewińska, et al.
Published: (2024) -
A PDE10A inhibitor CPL500036 is a novel agent modulating striatal function devoid of most neuroleptic side-effects
by: Mikolaj Matloka, et al.
Published: (2022) -
Design, Synthesis, and Development of Pyrazolo[1,5-<i>a</i>]pyrimidine Derivatives as a Novel Series of Selective PI3K<i>δ</i> Inhibitors: Part II-Benzimidazole Derivatives
by: Mariola Stypik, et al.
Published: (2022) -
Design, Synthesis, and Development of pyrazolo[1,5-<i>a</i>]pyrimidine Derivatives as a Novel Series of Selective PI3K<i>δ</i> Inhibitors: Part I-Indole Derivatives
by: Mariola Stypik, et al.
Published: (2022) -
Synthetic mRNA delivered to human cells leads to expression of Cpl-1 bacteriophage-endolysin with activity against Streptococcus pneumoniae
by: Moritz K. Jansson, et al.
Published: (2024)